Hemophilia Treatment Market

Hemophilia Treatment Market Research, 2031

The global hemophilia treatment market size was valued at $12.8 billion in 2021, and is projected to reach $26.9 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031. Hemophilia refers to a group of bleeding disorders, in which blood clotting takes a long time. It is categorized mainly in two forms, namely hemophilia A and hemophilia B. It is caused by the lack of clotting factor VIII or IX in the blood. In most cases, hemophilia is passed down through families (inherited). It is passed mostly to the male children. The main symptom of hemophilia is bleeding. Mild cases are expected to remain undetected until recognized after excessive bleeding following surgery or an injury. In severe cases, bleeding occurs for no reason. Internal bleeding may occur anywhere and bleeding into joints is common. It is diagnosed after a person has an abnormal bleeding episode. It can also be diagnosed by a blood test to detect the problem, if other family members have the condition. The primary treatment is to replace the missing clotting factor in the blood through a vein (intravenous infusions). Special care needs to be taken during surgery if you have this bleeding disorder. So, the surgeon operating the patient must be informed about having this disorder. It is also very important to share information about the disorder with blood relatives as they may also get affected with the disease.

The outbreak of COVID-19 had a negative impact on the hemophilia treatment market owing to the various stringent government restrictions for reducing hospital visits. The manufacturers were also hit by the pandemic effect with decrease in demand for hemophilia medicines.

The growth of the hemophilia treatment market share is driven by increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favorable government initiatives for hemophilia management.

The rise in R&D studies regarding treatment therapies in the segment, increase in target population, increase in diagnosis rate, and rise in the use of prophylactic treatment for hemophilia also contribute toward the hemophilia treatment market growth. However, high cost of hemophilia treatment, lack of medicines of hemophilia, and serious adverse effects associated with plasma derived products are expected to restrict the market growth. Conversely, the rise in the awareness about hemophilia in developing countries provides the hemophilia treatment market opportunity in the growth of the market.

Hemophilia Treatment Market Segmentation

The hemophilia treatment market is segmented into Type and Drug Therapy and Region. According to type, the market is divided into hemophilia A and hemophilia B. On the basis of drug therapy, the market is bifurcated into recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, non-factor replacement therapy, and others. Region-wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Market by Type Segment Review

By type, the hemophilia treatment market is categorized as hemophilia A and hemophilia B. The hemophilia A segment was the highest revenue contributor to the of hemophilia treatment industry during the forecast period, owing to the rise in incidence of hemophilia A and increased use of factor VIII. Hemophilia A is also projected to exhibit the fastest market growth rate of 7.6% during the forecast period, owing to technological advancements in treatment of hemophilia and product approval by the regulating authorities.

Market by Drug Therapy Segment Review

By drug therapy, the hemophilia treatment market is categorized as recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, non-factor replacement therapy, and others. The recombinant coagulation factor concentrates therapy segment was the highest revenue contributor to the hemophilia treatment market size during the forecast period owing to the increase in the number of recombinant technology products available for the treatment. Moreover, the non-factor replacement therapy segment is projected to exhibit the fastest market growth rate of 8.6% during the forecast period, owing to increase in target population and rise in research and development (R&D) activities on the treatment therapies.

Market by Region Segment Review

Europe was the highest revenue contributor in 2021 and is expected to remain dominant during the forecast period of hemophilia treatment industry. This was attributed to the research activities for hemophilia treatment, which are soaring in Europe, owing to the well-established healthcare facilities, recent technological advancements, and rise in demand for early diagnosis of hemophilia due to increase in awareness regarding the disease. Asia-Pacific is projected to register the highest CAGR of 8.3% during the forecast period, owing to increase in incidence of population suffering from hemophilia. In addition, increase in healthcare expenditure offers a lucrative opportunity for the market growth.

The major companies profiled in the report include Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols S.A., Swedish Orphan Biovitrium AB, Octapharma AG, and Medexus Pharmaceuticals Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemophilia treatment market analysis from 2021 to 2031 to identify the prevailing hemophilia treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hemophilia treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hemophilia treatment market trends, key players, market segments, application areas, and market growth strategies.

 Hemophilia Treatment Market Report Highlights